Tempus AI

CHICAGO--(BUSINESS WIRE)--May 5, 2026-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026.

04/03/2026 Utilizing real-world external controls for regulatory decision-making A biotech company needed to contextualize its Phase 1b/2a trial for mNSCLC patients with a specific mutation. Learn how Tempus constructed a real-world external control arm to provide a benchmark for their regulatory submission. 03/30/2026 Biomarker strategy for an inhibitor in bladder cancer Discover how Tempus’ multimodal data analysis helped a biotech partner identify a key biomarker in bladder cancer.

CHICAGO, March 17, 2026 – Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global nonprofit focused on blood cancer patient support, research, and advocacy, today announced a strategic collaboration to develop a comprehensive, patient-centered, real-world registry for pediatric acute myeloid leukemia (pAML), a rare and aggressive blood cancer.

01/20/2026 From image to insight: How Tempus is leveraging AI to advance biomarker screening at scale By leveraging Paige Predict to screen for genomic and phenotypic biomarkers, clinicians and researchers have rapid access to valuable information to prioritize testing and pre-screen patients at scale. 11/06/2025 This webinar explores the clinical value of MRD testing and IO treatment response monitoring in oncology, using real-world cases to illustrate its application in patient management.

CHICAGO, February 24, 2026 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2025.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that ten abstracts have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS). The meeting takes place December 9–12 at the Henry B. González Convention Center in San Antonio, Texas.

All registrants will be sent the webinar recording shortly following the completion of the session. All registrants will be sent the webinar recording shortly following the completion of the session. Join leaders from Tempus and Recursion for a candid discussion on their strategic partnership, which integrates petabytes of multimodal data with AI and supercomputing to advance drug discovery and development at scale.

CHICAGO, November 4, 2025 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended September 30, 2025.

HLTH USA 2025 October 19 – 22, 2025 The Venetian Expo Center We would love to discuss how we can collaborate with you to advance your longevity and wellness platforms. Our capabilities range from whole-genome sequencing to methylation-based biological age testing, providing novel health insights. We can customize our tests and reporting to fit your platform and user needs. Meet with a member of our team at HLTH USA to learn more.

Assess your cohort’s feasibility with our RWD Submit your preliminary criteria, and our team will provide a tailored feasibility assessment to help accelerate your research goals.* Thank you for contacting Tempus. We will respond shortly.